Quartus Capital Partners

Founder and Managing Partner Afzal M. Tarar leads the firm. The investment team is composed of operators and technologists whom the firm characterizes as AI pioneers averaging over 20 years of industry experience. Specific decision-making governance, including any investment committee structure beyond the managing partner, is not publicly disclosed.

Quartus describes its pipeline as derived from a knowledge edge built on the professional backgrounds and global networks of its partners. The firm states it concentrates on sectors where internal expertise provides an informational advantage, pointing to direct relationships rather than a formal intermediary-led sourcing model. No specific co-investor or venture-partner programs are described in public materials.

The firm targets growth-stage and mid-stage venture opportunities, typically from Series A through late-stage rounds. Its disclosed portfolio includes Series A, Series B and Series C positions, consistent with a venture growth mandate that seeks to invest after initial technology risk is reduced but before full commercial scale is achieved.

Available public disclosures indicate Quartus makes direct equity investments into portfolio companies. The firm does not describe any fund-of-funds activity or commitments to external venture capital or growth equity funds on its website or in its strategy materials.

The portfolio is concentrated at the intersection of AI and vertical-specific applications. Named positions span digital health — chronic disease management, neuro health diagnostics, wireless arthroscopy — as well as enterprise analytics, 3D LiDAR security, logistics, and sustainable materials recycling. The firm frames its mandate as AI and technology ventures addressing real-world challenges.

Quartus operates as an asset manager executing a generalist venture growth equity strategy, but its positioning emphasizes heavy operational engagement from a team of senior technologists rather than the lighter-touch board model common in early-stage VC. The firm cites the Cambridge Associates growth equity framework as a structural rationale, targeting venture-like upside with what it describes as buyout-style downside discipline.

No philanthropic foundation, donor-advised fund or separate non-investment vehicle is disclosed in public materials. The firm's website concentrates exclusively on its venture growth strategy and portfolio of direct investments.